A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic
neuropathic pain. People with diabetes can, over time develop nerve damage throughout the
body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms,
feet and legs.

Clinical Trial Conditions: Diabetic Neuropathic Pain

Treatments in this Clinical Trial : ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg – 18 mg, Placebo comparator, Duloxetine

Clinical Trial Phase: Phase 2

Eligible Clinical Trial Participant Age : Between 18 years to 75 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: Abbott

Detailed Clinical Trial Description: To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic
neuropathic pain. People with diabetes can, over time develop nerve damage throughout the
body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms,
feet and legs.

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01579279